Expert Analysis on Lack of Safety and Efficacy of C19 Shots

Ana Maria Mihalcea, MD, PhD - Sep 14, 2022 ∙ Paid ∙ Source

Likes: 30 | Comments: 7 | Reposts: 0 | ALL OTHER POSTS

Image Source: lawevidence.com

This shocking report is worth sharing and can be supporting evidence for any lawsuits as well as factual evidence to be shared with your loved ones and community. Please look at the abbreviated 18 points. For the full document, please see the PDF.

Here are 18 startling facts that you will discover in Dr Phillip Altman's Expert Report (August 2022) that analyses the lack of safety and efficacy of Covid-19 jabs. The Report is 43 pages in length, with 64 pages of appendices. To erase all doubt about the expertise of Dr Altman, his abbreviated CV is included after the 18 startling facts.

·         The worldwide use of COVID-19 gene-based ‘vaccines’ has been associated with far more deaths, illnesses, injuries, and disabilities than any other therapeutic agent in the entire history of medicine.

·         The TGA in Australia has received more Adverse Event reports in 2021 through June 2022 for the COVID-19 ‘vaccines’ than they have seen for all other vaccines in the preceding 50-year period.

·         Based on official UK and US data, all age groups under 50 years old are at greater risk of death after receiving a COVID-19 jab than an unjabbed person is at risk of a COVID-19 death.

·         PCR tests are no longer considered generally appropriate by the US Center for Disease Control (CDC) in determining the number of COVID-19 ‘cases’.

·         There is a statistically NEAR NIL RISK OF DEATH due to COVID-19 in very young children, adolescents, and adults through to middle-aged.

·         More than 99.995% of children and young people fully recover from SARS-CoV-2 infection.

·         Given the statistically NIL risk of serious COVID-19 affecting children up to 12 years of age and the clear risk of serious adverse effects including myocarditis, pericarditis and death in this age group – why would you jab these children?

·         The ACTUAL clinical efficacy to prevent even mild symptoms among 4500 ‘vaccine’ trial participants is less than 1%, not the 95% efficacy quoted by the jab manufacturers.

·         The long-term safety of the gene-based ‘vaccines’ is completely unknown and there are serious concerns which will only be resolved many years into the future.

·         As of 4 June 2022, 1,090 JABBED athletes suffered a cardiac arrest, with 715 of them dying as a result. The majority of these events occurred in competition or training. This is a huge increase! A 2009 review of professional athletes’ deaths, published in a European Cardiology journal, found that from 1966 to 2004, there was an average of only 29 sudden athlete deaths per year worldwide.

·         Extraordinarily high drops in birth rates are now apparent in Germany and Taiwan, (10% decline in Germany; 25% decline in Taiwan). Similar declines in birth rates are now being seen in USA, Sweden, Canada, and highly COVID-19 vaccinated Hungary.

·         Dr Rochelle Walensky, director of the CDC, said that “the COVID-19 vaccines can’t prevent transmission of SARS-CoV-2. This is basically because the COVID-19 vaccines do not prevent infection in an individual”.

·         It is wrong and dangerous to speak of a pandemic of the unvaccinated.

·         COVID-19 vaccinated individuals are more likely to be infected with COVID-19 and be admitted to hospital compared to non-vaccinated individuals.

·         Jabbed individuals have a 13x greater chance of infection compared to re-infection in the non-vaccinated group.

·         Naturally acquired immunity confers stronger protection against infection and symptomatic disease compared to ‘vaccine’-induced immunity.

·         In light of widely reported emerging and compelling evidence, there appears to be little scientific or clinical justification to support vaccine mandates as a health policy.

·         Many of the initial ambitious claims and assumed perceptions regarding the safety and efficacy of these therapeutics have now been invalidated and it is now time to review and reconsider the utility of these products in light of the known unprecedented level of serious adverse reactions and death attributed to their use.

You are urged to read the Altman Report to properly inform yourself, to enable you to make better decisions for you and your family.

Abbreviated Curriculum Vitae – Dr Phillip Altman

Dr Phillip Altman has expertise in the areas of clinical medical research and pharmaceutical drug regulatory affairs in Australia.

Holding the degrees Bachelor of Pharmacy (Hons), and Master of Science and Doctor of Philosophy, Phillip’s doctorate concerned the development new of cardiotonic drugs with lower intrinsic toxicity, compared to existing drugs including their chemical synthesis and testing in various animal models.

Phillip has worked primarily within the Australian pharmaceutical industry since 1974 in relation to clinical trial design, management, and reporting in relation to obtaining new drug approvals, dealing with the Secretary of the Department of Health, and the Therapeutic Goods Administration ( TGA ).

After many years working within multinational pharmaceutical companies, Phillip later became a senior industry pharmaceutical consultant through his contract research company, Pharmaco Pty Ltd., which provided both clinical trial and regulatory consultant services to the Australian pharmaceutical industry, which focussed his experience in critically evaluating clinical trial safety and efficacy data, as submitted in complex new drug dossiers for international regulatory purposes. This work saw Phillip consulted by more than half of the multinational pharmaceutical companies in Australia, in various capacities, with a focus on drug regulatory affairs.

Phillip founded the Association of Regulatory and Clinical Scientists (ARCS), which includes more than 2,000 scientists, clinicians, and associated health professionals involved in both clinical trial and regulatory affairs, in Australia and New Zealand, where ARCS continues to be the foremost educational forum for both industry and government (including the TGA) personnel, involved in clinical trials and regulatory affairs.

Phillip’s experience involves more than 100 clinical trials (covering Phases I,II, III and IV, i.e. from first administration to animals, then man, to post-approval trials), and a similar number of new drug applications, TGA appeals, and applications to modify existing approvals. In collaboration with the TGA and on behalf of pharmaceutical companies, Phillip also directed 2 major drug withdrawals in relation to public safety.

More recently Phillip has been a senior clinical trial and regulatory affairs advisor to an Australian company which has developed a live virus for the treatment of melanoma.

Likes: 30 | Comments: 7 | Reposts: 0 | Share Options: Copy Link

Comments